Marina Biotech
Marina Biotech is a City of Industry, California-based pharmaceutical company specializing in RNAi-based drug discovery and RNA-based therapeutics, with 11 to 50 employees and an OTCQB listing under MRNA. No active products, customers, or partnerships are publicly disclosed.
- Company typePrivate
- Founded1983
- HeadquartersCity Of Industry, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Marina Biotech firmographics
Firmographics- Name
- Marina Biotech
- Legal name
- Marina Biotech Inc.
- Website
- https://marinabio.com
- Company type
- Private
- Founded year
- 1983
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Marina Biotech is a City of Industry, California-based pharmaceutical company specializing in RNAi-based drug discovery and RNA-based therapeutics, with 11 to 50 employees and an OTCQB listing under MRNA. No active products, customers, or partnerships are publicly disclosed.
- Ownership category
- akta.pro rank
Marina Biotech industry classification
Industry- Product category
- RNA-based Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
Keywords
Where Marina Biotech is headquartered
LocationHeadquarters
- HQ city
- City Of Industry
- HQ country
- United States
- HQ region
- North America
Markets served
Marina Biotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Marina Biotech product offering
Product offeringCore offering
Marina Biotech is a pharmaceutical company that specializes in RNAi-based drug discovery and the development of RNA-based therapeutics. The company applies nucleic-acid delivery and RNA interference technologies to identify and advance therapeutic candidates, with a focus on disease pathways including beta-catenin-related targets.
Differentiator
Problem solved
Functional benefit
Products and services
- RNAi-Based Drug Discovery and RNA-Based Therapeutics Core research and development platform focused on identifying and advancing RNA interference (RNAi) and RNA-based therapeutic candidates, with applications in disease areas such as beta-catenin-related indications, intended for pharmaceutical partners and licensees.
Companies that use Marina Biotech
Customer profileIdeal customer profiles1 record
Marina Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Marina Biotech partnerships and signals
Strategic signalScale indicators1 record
Marina Biotech competitors and assessment
Company assessmentDirect peers
- Alnylam Pharmaceuticals: The leading commercial-stage RNAi therapeutics company (patisiran, givosiran, inclisiran). Directly comparable to Marina Biotech as both develop RNAi-based drugs, though Alnylam is vastly larger and clinically advanced.
- Ionis Pharmaceuticals: Antisense oligonucleotide (ASO) and RNA-targeted therapeutics company with multiple approved products (Spinraza, Tegsedi). Highly comparable to Marina Biotech's RNA-based therapeutic focus.
- Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with a broad pipeline using multiple delivery platforms. Direct competitor in the same RNAi drug discovery space as Marina Biotech.
- Silence Therapeutics: Clinical-stage RNAi therapeutics company developing siRNA candidates. Comparable in modality and target disease areas to Marina Biotech's RNAi-based discovery work.
- Wave Life Sciences: Clinical-stage RNA therapeutics company using PRISM platform for stereopure oligonucleotide drugs. Direct peer in RNA-based therapeutic development.
- Dicerna Pharmaceuticals: RNAi therapeutics developer (acquired by Novo Nordisk in 2021). Marina Biotech is explicitly grouped alongside Dicerna in the same Beta Catenin market analysis, making it a near-perfect direct peer.
- ProQR Therapeutics: RNA-based therapeutics company developing Axiomer RNA editing technology. Comparable in modality (RNA-based drugs) and target indications, though with a different RNA editing mechanism.
Broad incumbents
- Moderna: Major mRNA therapeutics and vaccines company. Comparable as a broad RNA therapeutics incumbent, though Marina Biotech focuses on RNAi rather than mRNA and is dramatically smaller.
Emerging players
- Propanac Biopharma: Listed alongside Marina Biotech as one of the key companies in the Beta Catenin Market 2026-2033 analysis, indicating a comparable niche oncology-RNA focus.
Regional players
- Boston Biomedical: Identified alongside Marina Biotech in the Beta Catenin Market report. Oncology-focused company (a subsidiary of Sumitomo Dainippon Pharma), comparable as a peer in β-catenin pathway drug development.
Market position
Customer concentration
Marina Biotech social profiles
Digital presenceMarina Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Marina Biotech leadership team
Management profileNumber of profiles
Profiles8 records
Marina Biotech funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Marina Biotech M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Marina Biotech
What does Marina Biotech do?
Marina Biotech is a pharmaceutical company that specializes in RNAi-based drug discovery and the development of RNA-based therapeutics. The company applies nucleic-acid delivery and RNA interference technologies to identify and advance therapeutic candidates, with a focus on disease pathways including beta-catenin-related targets.
Is Marina Biotech a public or private company?
Marina Biotech is a private company. It is classified as public and is currently operating.
When was Marina Biotech founded?
Marina Biotech was founded in 1983. It employs 11 to 50 people.
Where is Marina Biotech based?
Marina Biotech is headquartered in City Of Industry, United States, in the North America region.
Who are Marina Biotech's main competitors?
Direct peers on record are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Wave Life Sciences, Dicerna Pharmaceuticals and ProQR Therapeutics. Moderna is listed as a broad incumbent. Propanac Biopharma is listed as an emerging player. Boston Biomedical is listed as a regional player.
Does Marina Biotech have an API?
No public API is recorded for Marina Biotech.
What industry is Marina Biotech in?
Marina Biotech's product category is RNA-based Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAF, RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC). Its NAICS code is 325414 and its SIC code is 2834.